Clinical experience with a new hemodiafiltration (HDF) system.

Area of Science:

• Nephrology
• Medical Device Technology
• Biotechnology

Background:

• Purity of fluids is critical for high-flux, high-efficiency renal replacement therapies like hemodiafiltration (HDF).
• Sterile, pyrogen-free substitution fluid bags contribute significantly to the high cost of these treatments.
• Bicarbonate concentrates are often used in these therapies, necessitating fluid purity.

Purpose of the Study:

• To evaluate a novel monitoring system (MPS-10, Gambro) for preparing reinfusion fluid from bicarbonate dialysate via filtration.
• To assess the safety and efficacy of the MPS-10 system for on-line HDF treatments.

Main Methods:

• The MPS-10 system was used to prepare reinfusion fluid from bicarbonate dialysate through filtration.
• On-line HDF treatments were conducted over a 5-month period in five chronic uremic patients.
• Fluid purity (bacterial and endotoxin levels) and weight balance were monitored.

Main Results:

• The prepared infusion fluid and dialysate were found to be free from bacteria and endotoxins.
• The MPS-10 system achieved correct weight balance during the on-line HDF treatments.
• No adverse events related to fluid quality were reported during the study period.

Conclusions:

• The MPS-10 system is a safe and effective method for producing sterile, pyrogen-free dialysate and reinfusion fluid.
• This system offers a potential solution to reduce the costs associated with substitution fluid bags in HDF, hemodialysis (HD), and hemofiltration (HF).
• The technology supports advanced renal replacement therapies by ensuring fluid safety and potentially improving economic efficiency.